Antenatal screening for Down syndrome in New Zealand: Time for a national screening policy?

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 2, 2006, Pages 92-96

  Chang, Tou Choong ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; AMNIOCENTESIS; ARTICLE; AUSTRALIA; BIRTH RATE; BLOOD CHEMISTRY; CHORION VILLUS SAMPLING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FIRST TRIMESTER PREGNANCY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; NEW ZEALAND; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT ATTITUDE; PRENATAL SCREENING; PRIORITY JOURNAL; REGIONALIZATION; SECOND TRIMESTER PREGNANCY;

AUSTRALIA; DOWN SYNDROME; FEMALE; GENETIC SCREENING; HUMANS; NATIONAL HEALTH PROGRAMS; NEEDS ASSESSMENT; POLICY MAKING; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL CARE; ULTRASONOGRAPHY, PRENATAL;

EID: 33645366459     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00534.x     Document Type: Article

References (50)

1. Stone P. Prenatal testing for aneuploidy in New Zealand: Time for action. N Z Med J 2005; 118: U1545.
2. RANZCOG. Joint HGSA / RANZCOG prenatal diagnosis policy. RANZCOG College Statement C-Obs 5. March 2004; 1-4.
3. Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling. Am J Med Genet 2005; 133: 31-36.
4. Reid R. Detection of Down's syndrome -response. N Z Med J 2003; 116: 526.
5. RANZCOG. Joint HGSA / RANZCOG recommended 'Best Practice' Guidelines on antenatal screening for Down syndrome and other fetal aneuploidy. RANZCOG College Statement C-Obs 4. March 2004; 1-3.
6. O'Callaghan SP, Giles WB, Raymond SP, McDougall V, Morris K, Boyd J. First trimester ultrasound with nuchal translucency measurement for Down syndrome risk estimation using software developed by the Fetal Medicine Foundation, United Kingdom: The first 2000 examinations in Newcastle, New South Wales, Australia. Aust N Z J Obstet Gynaecol 2000; 40: 292-295.
7. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191: 45-67.
8. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: A Scottish multicentre study. BJOG 2002; 109: 667-676.
9. Herman A, Dreazen E, Maymon R, Tovbin Y, Bukovsky I, Weinraub Z. Implementation of nuchal translucency image-scoring method during ongoing audit. Ultrasound Obstet Gynecol 1999; 14: 388-392.
10. Wojdemann KR, Christiansen M, Sundberg K, Larsen SO, Shalmi A, Tabor A. Quality assessment in prospective nuchal translucency screening for Down syndrome. Ultrasound Obstet Gynecol 2001; 18: 641-644.
11. Snijders RJ, Thom EA, Zachary JM et al. First-trimester trisomy screening: Nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19: 353-359.
12. Theodoropoulos P, Lolis D, Papageorgiou C, Papaioannou S, Plachouras N, Makrydimas G. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age. Prenat Diagn 1998; 18: 133-137.
13. Zoppi MA, Ibba RM, Floris M, Monni G. Fetal nuchal translucency screening in 12 495 pregnancies in Sardinia. Ultrasound Obstet Gynecol 2001; 18: 649-651.
14. Gasiorek-Wiens A, Tercanli S, Kozlowski P et al. Screening for trisomy 21 by fetal nuchal translucency and maternal age: A multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 2001; 18: 645-648.
15. Brizot MA, Carvalho MHB, Liao AW, Reis SV, Armbruster-Moraes E, Zugaib M. First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Ultrasound Obstet Gynecol 2001; 18: 652-655.
16. Chasen ST, Sharma G, Kalish RB, Chervenak FA. First-trimester screening for aneuploidy with fetal nuchal translucency in a United States population. Ultrasound Obstet Gynecol 2003; 22: 149-151.
17. Thilaganathan B, Sairam S, Michailidis G, Wathen NC. First trimester nuchal translucency: Effective routine screening for Down's syndrome. Br J Radiol 1999; 72: 946-948.
18. Prefumo F, Thilaganathan B. Agreement between predicted risk and prevalence of Down syndrome in first trimester nuchal translucency screening. Prenat Diagn 2002; 22: 917-918.
19. Snijders RJ, Noble P, Sebire N et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346.
20. Wald NJ, Rodeck C, Hackshaw AK et al. First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-88.
21. Malone FD, Wald NJ, Canick JA et al. First- and second-trimester evaluation of risk (FASTER) trial: Principal results of the NICHD multicenter Down syndrome screening study. Am J Obstet Gynecol 2004; Abstract 1.
22. Bahado-Singh RO, Choi SJ, Cheng CC. First- and mid-trimester Down syndrome screening and detection. Clin Perinatol 2004; 31: 677-694.
23. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96: 207-213.
24. Bindra R., Heath V, Liao A, Spencer K, Nicolaides KH. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: A prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-225.
25. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies; a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000; 107: 1271-1275.
26. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: A review of three years prospective experience. BJOG 2003; 110: 281-286.
27. Schuchter K, Hafner E, Stangl G, Metzenbauer M, Hofinger D, Philipp K. The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 2002; 22: 211-215.
28. Wapner R., Thom E, Simpson JL et al. First trimester maternal serum biochemistry and fetal nuchal translucency screening (BUN) study group: first trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349: 1405-1413.
29. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 2004; 24: 774-780.
30. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
31. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004; 24: 762-766.
32. Sangalli M, Langdana F, Thurlow C. Pregnancy loss rate following routine genetic amniocentesis at Wellington Hospital. N Z Med J 2004; 117: 818-823.
33. Reid KP, Gurrin LC, Dickinson JE, Newnham JP, Phillips JM. Pregnancy loss rates following second trimester genetic amniocentesis. Aust N Z J Obstet Gynaecol 1999; 39: 281-285.
34. Scott F, Peters H, Boogert T et al. The loss rates for invasive prenatal testing in a specialized obstetric ultrasound practice. Aust N Z J Obstet Gynaecol 2002; 42: 55-58.
35. Spencer K, Aitken D. Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet Gynecol 2004; 24: 735-739.
36. Rostant K, Steed L, O'Leary P. Survey of the knowledge, attitudes and experiences of Western Australian women in relation to prenatal screening and diagnostic procedures. Aust N Z J Obstet Gynaecol 2003; 43: 134-138.
37. Mulvey S, Zachariah R., McIlwaine K, Wallace EM. Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate? Prenat Diagn 2003; 23: 828-832.
38. Cederholm M, Axelsson O, Sjoden P-O. Women's knowledge, concerns and psychological reactions before undergoing an invasive procedure for prenatal karyotyping. Ultrasound Obstet Gynecol 1999; 14: 267-272.
39. Hewison J. Psychological aspects of integrated testing. BJOG 2004; 111: 519-520.
40. Jaques AM, Bell RJ, Watson L, Halliday JL. People who influence women's decisions and preferred sources of information about prenatal testing for birth defects. Aust N Z J Obstet Gynaecol 2004; 44: 233-238.
41. van den Berg M, Timmermans DR, Ten Kate LP, van Vugt JM, van der Wal G. Are pregnant women making informed choices about prenatal screening? Genet Med 2005; 7: 332-338.
42. Suriadi C, Jovanovska M, Quinlivan JA. Factors affecting mothers' knowledge of genetic screening. Aust N Z J Obstet Gynaecol 2004; 44: 30-34.
43. Caughey AB, Kuppermann M, Norton ME, Wahington AE. Nuchal translucency and first trimester biochemical markers for Down syndrome screening: A cost-effectiveness analysis. Am J Obstet Gynecol 2002; 187: 1239-1245.
44. Cusick W, Buchanan P, Hallahan TW et al. Combined first trimester versus second-trimester serum screening for Down syndrome: A cost analysis. Am J Obstet Gynecol 2003; 188: 745-751.
45. Cheffins T, Chan A, Haan EA et al. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG 2000; 107: 1453-1459.
46. Mulvey SF, Atchison WG, Grimwade JC, Renou PM, Shekleton PA, Wallace EM. The utilization of nuchal translucency as a prenatal marker of Down syndrome, 1993-99. Aust NZ J Obstet Gynaecol 2000; 40: 423-426.
47. Report of the Birth Defects Registry of Western Australia 1980-2004. [Cited Nov 2005.] Available from: http://wchs.health.wa.gov.au/services/ birth_defects/4596.pdf
48. Lawrence K, Crowther CA. Survey of current prenatal screening for Down syndrome in Australian hospitals providing maternity care. Aust NZ J Obstet Gynaecol 2003; 43: 222-225.
49. Cicero S, Bindra R., Rembouskos G et al. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn 2003; 23: 306-310.
50. Bloomfield A, Tuohy P. Detection of Down's syndrome. N Z Med J 2003; 116: 526.